![David Allmond](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Allmond
Keine laufenden Positionen mehr
Profil
David Allmond formerly worked at Novacyt SA, as Chief Executive Officer & Director from 2021 to 2022, Myeloma UK, as Director, Celgene Corp., as Vice President-Global Marketing from 2006 to 2012, Aegerion Pharmaceuticals, Inc., as President-Europe, Middle East & Africa Regions, Amryt Pharma Holdings Ltd., as Chief Commercial Officer from 2017 to 2020, and Poolbeg Pharma Plc, as Chief Business Officer from 2023 to 2025.
Mr. Allmond received his undergraduate degree from Imperial College London.
Ehemalige bekannte Positionen von David Allmond
| Unternehmen | Position | Ende |
|---|---|---|
| POOLBEG PHARMA PLC | Corporate Officer/Principal | 01.11.2025 |
| NOVACYT | Vorstandsvorsitzender | 09.11.2022 |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for patients with rare and orphan diseases | Corporate Officer/Principal | 01.09.2020 |
| CELGENE | Vertrieb & Marketing | 01.01.2012 |
Myeloma UK
 Myeloma UK Medical/Nursing ServicesHealth Services Provides support services for patients suffering from myeloma | Direktor/Vorstandsmitglied | - |
Ausbildung von David Allmond
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
51
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novacyt SAS
 Novacyt SAS Medical SpecialtiesHealth Technology Designs, develops and markets molecular real-time PCR testing devices and reagents in the areas of infectious diseases | Health Technology |
Myeloma UK
Myeloma UK Medical/Nursing ServicesHealth Services Provides support services for patients suffering from myeloma | Health Services |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for patients with rare and orphan diseases | Health Technology |
Poolbeg Pharma Plc
 Poolbeg Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a clinical stage infectious disease curing pharmaceutical company | Health Technology |
Wählen Sie MarketScreener 
